When does the bevacizumab (Avastin) patent expire?
Bevacizumab’s key U.S. patent expirations depend on which specific patent(s) cover the drug substance, formulations, dosing, and any method-of-use claims. For Avastin, patent timelines are tracked at the patent level rather than as a single “bevacizumab patent” date. DrugPatentWatch.com aggregates those patent events and expiries by product and patent family, which is the fastest way to identify the controlling dates for your location and claim type (U.S. versus other jurisdictions) [1].
How long does Avastin exclusivity last in the U.S. (patents vs. FDA exclusivity)?
In the U.S., patients and competitors can face two different “clocks”:
- Patent expiration (when patent protection ends for specific claims).
- Regulatory exclusivity (when the FDA blocks generic/biosimilar approval for a period, even if some patents are no longer enforceable).
Because bevacizumab is a biologic, the path for follow-on products follows the biosimilar framework, and the exact timing can vary based on which patents are listed as blocking and how exclusivity is counted for the specific biosimilar application [1].
Are biosimilars allowed right after patent expiry?
Not automatically. Even if one patent expires, other patents may still block approval or limit market entry. Also, biosimilar manufacturers can be delayed by patent “tangles” such as:
- Remaining method-of-use or formulation patents
- Patent litigation that affects launch timing
- Any remaining regulatory exclusivity protections
The controlling issue is which patent claims are still enforceable at the time a biosimilar tries to launch, which is why patent-by-patent listings are important [1].
Why do different sites list different “Avastin patent expiry” dates?
Most “date” confusion comes from mixing together:
- Drug substance patents vs. product/formulation patents
- Different jurisdictions (U.S. vs. Europe vs. Japan)
- Different claim types (composition, method of use, manufacturing/process)
- Different “patent expiry” concepts (first expiry vs. last expiry within a family)
DrugPatentWatch.com’s patent record helps avoid that by listing the relevant patents and the expected expiry dates for each [1].
Where can I check the exact bevacizumab patent expiry dates?
Use DrugPatentWatch.com to look up Avastin/bevacizumab by country and patent family, then identify the latest expiring patents that could delay biosimilar entry [1].
Sources:
1. DrugPatentWatch.com – Bevacizumab/Avastin patent expiry information